Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Raymond James Financial, Inc. (RJF) vs Zoetis Inc (ZTS) Price & Performance

Raymond James Financial, Inc.Trade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Raymond James Financial, Inc. vs Zoetis Inc — how do they compare? Raymond James Financial, Inc. trades at $157.94 (market cap $30.51B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Raymond James Financial, Inc. and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and Zoetis Inc for 70 Days on average.

RJFZTS
Market Cap
$30.51B$30.20B
Volume
1,206,2536,175,327
Sector
FinancialsHealth
52-Week High
$181.18$147.53
52-Week Low
$140.89$69.09
Typical Hold Time
75 Days70 Days
Enterprise Value
$24.37B$37.76B
Dividend Yield
1.36%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Raymond James Financial, Inc.

Raymond James Financial (RJF) trades at $159.04, up 1.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 estimate. Revenue has grown steadily from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. A quarterly dividend of $0.54 was declared, payable in October 2026.

The outlook is supported by solid fundamentals, including a P/E of 13.83 and ROE of 18.48%, but risks include volatile cash flows from investing activities and rising expenses. Analysts are neutral with a consensus price target of $184.00, implying potential upside. Investor sentiment is mixed amid recent institutional buying and selling activity.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

About Raymond James Financial, Inc.

Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.

Read more on RJF →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →